FLC Capital Advisors Makes New Investment in GSK plc (NYSE:GSK)

FLC Capital Advisors acquired a new stake in GSK plc (NYSE:GSK - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 8,238 shares of the pharmaceutical company's stock, valued at approximately $279,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. M.E. Allison & CO. Inc. acquired a new stake in shares of GSK in the 4th quarter valued at approximately $314,000. J2 Capital Management Inc acquired a new stake in GSK in the fourth quarter valued at $596,000. HF Advisory Group LLC boosted its position in shares of GSK by 12.8% during the 4th quarter. HF Advisory Group LLC now owns 8,743 shares of the pharmaceutical company's stock worth $296,000 after purchasing an additional 990 shares in the last quarter. Ameritas Advisory Services LLC grew its stake in shares of GSK by 19.4% during the 4th quarter. Ameritas Advisory Services LLC now owns 34,955 shares of the pharmaceutical company's stock worth $1,182,000 after purchasing an additional 5,668 shares during the period. Finally, HB Wealth Management LLC acquired a new position in GSK during the fourth quarter worth about $316,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Performance

NYSE GSK traded up $0.02 during trading hours on Monday, reaching $33.46. The company's stock had a trading volume of 3,930,425 shares, compared to its average volume of 2,865,091. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The business has a 50-day simple moving average of $34.02 and a 200 day simple moving average of $37.97. The stock has a market cap of $69.34 billion, a PE ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were given a dividend of $0.3928 per share. The ex-dividend date of this dividend was Friday, November 15th. This is an increase from GSK's previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.70%. GSK's payout ratio is currently 96.10%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft downgraded GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Guggenheim lowered shares of GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Monday, January 13th. Finally, Jefferies Financial Group downgraded shares of GSK from a "buy" rating to a "hold" rating and cut their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, GSK has an average rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.